Abstract 278P
Background
Radical chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancer (LAHNC). For mitigating the normal tissue toxicity, many techniques have been explored and utilized, including IMRT and adaptive radiotherapy (ART). Significant anatomical variations occur during CTRT due to weight loss and tumor and normal tissue changes. In the present study, serial changes in parotid volumes were assessed with weekly scans along with dosimetric correlation.
Methods
This prospective, single-institutional study, included 12 patients with LA HNC receiving CTRT. All underwent CT simulation (CT sim) followed by weekly rescans from week 1 to 6. Target volumes and organs at risk, including right & left parotids (RP & LP) were recontoured in all rescans after fusion with the CT sim. Dose overlay was done in each rescan to generate a hybrid plan to study corresponding dosimetric variations. Volume changes in parotids were reported as percentage change from the baseline.
Results
In CT sim, right parotid volumes (RPV) ranged from 15.7 - 44.2 cc (mean - 24.1 SD – 7.9) and left parotid volume (LPV) from 12.2 - 47.1 cm3 (mean 22.8, SD -9.9). Mean % reduction in RPV in week 1, 2, 3, 4, 5 and 6 were 14.2% (p=0.003), 17.1% (p=0.007), 21.8% (p < 0.001), 25.6% (p < 0.001), 30% (p < 0.001), 32.1% (p < 0.001) respectively. Mean % reduction in LPV in week 1, 2, 3, 4, 5 and 6 were 8.9% (p=0.016), 14.5% (p=0.012), 17.7% (p=0.001), 20.1% (p=0.002), 24.9% (p < 0.001), 28.9% (p < 0.001) respectively. LP D mean showed a significant increase in week 3 (4.6% from baseline, p=0.019) and week 6 (7.6% from baseline, p=0.034). Both parotids showed a significant reduction in V26 Gy with 12.3%, 15.1%, 18.9%, 22.9%, 25.7%, 27.0%, respectively, from week 1 to 6 in RP and 7.3%, 15.7%, 13.8%, 16.8%, 20.8%, 24.1%, respectively, in LP.
Conclusions
Parotid volume shrinkage started from the 1st week. At the end of CTRT, there was 30-32% reduction in volume. V26 Gy of both parotids showed significant reduction during CTRT. Studies focusing on parotid volume changes shows wide variations in volume reduction ranging from 13% to 50% at the end of treatment. These parotid volume changes during RT need to be incorporated while doing ART in LAHNC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uttarakhand.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
413P - South Korean real-world treatment patterns in patients with EGFRm NSCLC
Presenter: Jae Cheol Lee
Session: e-Poster Display Session
414P - Incidence and characteristics of lung cancer diagnosed after kidney transplantation at the National Kidney and Transplant Institute
Presenter: Adeline Gonzales
Session: e-Poster Display Session
415P - Real-world fusion landscape of RET gene fusions and its response to cabozantinib in Chinese non-small cell lung cancer (NSCLC) using next generation sequencing
Presenter: Chunwei Xu
Session: e-Poster Display Session
416P - A single institute study evaluating the additional benefit of blood NGS testing over conventional molecular testing in metastatic adenocarcinoma lung
Presenter: Rajashree Ashwath
Session: e-Poster Display Session
417P - Efficacy and safety of lorlatinib in subsequent lines of therapy in ALK and ROS1 positive lung cancer
Presenter: Amit Kumar
Session: e-Poster Display Session
418P - All EGFR mutations are (not) created equal: Focus on uncommon EGFR mutations
Presenter: Ullas Batra
Session: e-Poster Display Session
419P - Surgical treatment of malignant tumours and metastatic lesions of the chest wall
Presenter: Zhanat Pyssanova
Session: e-Poster Display Session
421P - A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated thyroid cancer (RR-DTC) in China
Presenter: Ming Gao
Session: e-Poster Display Session
422P - Response rate and time to progression after first line chemotherapy with cisplatin and adriamycin in patients with metastatic osteosarcoma at presentation
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
423P - Positive lymph node and thicker Breslow are associated with poor prognosis of high-risk resected melanomas
Presenter: Roby Cahyono
Session: e-Poster Display Session